Birmingham Capital Management Co. Inc. AL Has $3.22 Million Stock Position in Abbott Laboratories $ABT

Birmingham Capital Management Co. Inc. AL lowered its stake in Abbott Laboratories (NYSE:ABT) by 0.8% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 24,280 shares of the healthcare product maker’s stock after selling 200 shares during the quarter. Abbott Laboratories makes up approximately 1.2% of Birmingham Capital Management Co. Inc. AL’s investment portfolio, making the stock its 28th largest position. Birmingham Capital Management Co. Inc. AL’s holdings in Abbott Laboratories were worth $3,221,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Hughes Financial Services LLC acquired a new stake in shares of Abbott Laboratories in the first quarter valued at about $27,000. Abound Financial LLC acquired a new stake in Abbott Laboratories in the 1st quarter valued at about $28,000. Elequin Capital LP acquired a new stake in Abbott Laboratories in the 1st quarter valued at about $30,000. Wormser Freres Gestion acquired a new stake in Abbott Laboratories in the 4th quarter valued at about $32,000. Finally, JCIC Asset Management Inc. acquired a new position in Abbott Laboratories in the 1st quarter valued at about $32,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on ABT shares. Mizuho increased their target price on Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 16th. Raymond James Financial lowered their target price on Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating on the stock in a research note on Friday, July 18th. Evercore ISI lifted their price objective on shares of Abbott Laboratories from $140.00 to $145.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 8th. Jefferies Financial Group raised Abbott Laboratories from a “hold” rating to a “buy” rating and boosted their target price for the stock from $143.00 to $145.00 in a research note on Friday, July 18th. Finally, Wells Fargo & Company lowered their target price on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a research note on Friday, July 18th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $144.47.

Abbott Laboratories Price Performance

Shares of ABT opened at $129.39 on Thursday. Abbott Laboratories has a 1 year low of $110.86 and a 1 year high of $141.23. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The company has a market capitalization of $225.20 billion, a price-to-earnings ratio of 16.21, a price-to-earnings-growth ratio of 2.50 and a beta of 0.69. The business has a 50-day moving average of $130.43 and a 200-day moving average of $131.35.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. During the same quarter in the prior year, the company earned $1.14 EPS. The firm’s revenue for the quarter was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, August 15th. Investors of record on Tuesday, July 15th were paid a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend was Tuesday, July 15th. Abbott Laboratories’s dividend payout ratio is 29.57%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.